| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4030002 | Ophthalmology | 2007 | 7 Pages |
Abstract
These results suggest that a single intravitreal injection of bevacizumab is well tolerated and is associated with short-term improvement in VA and decreased OCT retinal thickness in a considerable proportion of patients with uveitic CME resistant to conventional therapy. Further evaluation of intravitreal bevacizumab for uveitic CME in controlled randomized studies is warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Miguel MD, Lucia MD, Sumru MD, William PhD, C. Stephen MD,